secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001628280-25-023482
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine Q1 2025 net loss $51.9M; cash $158.3M; pipeline on track for CGD data in 2025
--------------------------------------------------------------------------------

- Net loss $51.9M (vs $45.8M Q1 2024); R&D $40.6M, G&A $13.3M.
- Cash, equivalents, investments $158.3M as of March 31, 2025, down from $204.5M at Dec 31, 2024.
- Initial Phase 1/2 data for PM359 (p47 phox CGD) expected in 2025.
- IND/CTA for PM577 (Wilson's Disease) on track for 1H 2026; AATD program unveiled with IND/CTA mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828025023482/0001628280-25-023482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828025023482/prme-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-023482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer